To MSNAP or not to MSNAP? Testing a small regional memory clinic against the UK Memory Service National Accreditation Program (MSNAP)

Autor: E. B. Sweeney, A. Denihan, S. Fitzsimons, J. E. Foley

Publikováno v: Irish Journal of Psychological Medicine. 36:145-151

AimTo investigate whether a small regional memory clinic would benefit from engaging with a structured external audit process such as the Royal College of Psychiatrists’ Memory Service National Accreditation Program (MSNAP).BackgroundThe Psychiatry

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61f215c050bec78ac39da7975b6085dd
https://doi.org/10.1017/ipm.2018.14

Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial

Autor: C. Pan, W. Yang, J. P. Barona, Y. Wang, M. Niggli, P. Mohideen, J. E. Foley

Publikováno v: Diabetic Medicine. 25:435-441

Aims To compare the efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor, vildagliptin, with the alpha glucosidase inhibitor, acarbose, in drug-naive patients with Type 2 diabetes. Methods This multi-centre, randomized, double-blind, par

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15c85210bd0fc289b59721ddc3204328
https://doi.org/10.1111/j.1464-5491.2008.02391.x

Improved Meal-related Insulin Processing Contributes to the Enhancement of B-Cell Function by the DPP-4 Inhibitor Vildagliptin in Patients with Type 2 Diabetes

Autor: Anja Schweizer, Bo Ahrén, Andrea Tura, G. Pacini, J. E. Foley

Publikováno v: Hormone and metabolic research 39 (2007): 826–829.
info:cnr-pdr/source/autori:Ahren B, Pacini G, Tura A, Foley JE and Schweizer A,/titolo:Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes/doi:/rivista:Hormone and metabolic research/anno:2007/pagina_da:826/pagina_a:829/intervallo_pagine:826–829/volume:39

The aim of this study was to evaluate the contribution of insulin processing to the improved meal-related B-cell function previously shown with the DPP-4 inhibitor vildagliptin. Fifty-five patients with type 2 diabetes (56.5+/-1.5 years; BMI=29.6+/-0

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e8d600ddc442afa8da37fc6ef3d11f6
https://doi.org/10.1055/s-2007-991172

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

Autor: Anja Schweizer, J E Foley, Bo Ahrén, Johan Farngren, Margaretha Persson

Publikováno v: Diabetes, obesitymetabolism. 16(9)

To determine the effects of dipeptidyl peptidase-4 (DPP-4) inhibition on glucagon dynamics in patients with insulin-treated type 2 diabetes (T2D).The study was a single-centre, double-blind, randomized, placebo controlled crossover study in patients

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afa0e9a54f187b02d744b7c576d8a8ce
https://pubmed.ncbi.nlm.nih.gov/24612221

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

Autor: B. Zinman, D. R. Matthews, Bo Ahrén, S. Dejager, Vivian Fonseca, J. E. Foley, A. Couturier, Ele Ferrannini

Publikováno v: Diabetes, obesitymetabolism. 12(9)

AIM: To show that vildagliptin added to metformin is non-inferior to glimepiride in reducing HbA1c levels from baseline over 2 years. METHODS: A randomized, double-blind, active-comparator study of patients with type 2 diabetes mellitus inadequately

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fae336ebc34dbe15fc327a6aedd3658f
https://pubmed.ncbi.nlm.nih.gov/20649630